Alzheimers Medical Advisor: A Symptom and Sign Management Toolkit for Caregivers
阿尔茨海默病医疗顾问:针对护理人员的症状和体征管理工具包
基本信息
- 批准号:8867050
- 负责人:
- 金额:$ 48.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-09-27 至 2016-06-30
- 项目状态:已结题
- 来源:
- 关键词:Accident and Emergency departmentAcuteAddressAdoptedAgeAgitationAlzheimer&aposs DiseaseAnxietyAreaBehavioralBehavioral SymptomsCaregiversCaringClinical TrialsCollaborationsCommunicationComorbidityConsultationsDataDecision MakingDehydrationDementiaDevelopmentDiscipline of NursingDiseaseDisease ProgressionEducationEffectivenessEmergency department visitEvaluationFamilyFamily CaregiverFamily memberFeverFocus GroupsGoalsHealthHealth PersonnelHealth ProfessionalHealth systemHome environmentHospital DepartmentsHospitalizationInternetInterventionKnowledgeLifeLiteratureMeasuresMedicalMental DepressionModificationMonitorNorth CarolinaNursesNursing ProtocolsOutcomePainPain MeasurementParticipantPersonsPredispositionPrimary Health CarePrintingProtocols documentationProviderProxyPsychometricsRaceReadingRecommendationReportingResearchResourcesRestSelf EfficacySeriesServicesShortness of BreathSigns and SymptomsSiteSymptomsSystemTechniquesTestingTimeTrainingTriageUniversitiesVisitbasecognitive testingcostdecision-making capacitydesigneighth gradeevidence basefrailtyhealth care service utilizationhealth literacyimplementation trialimprovedmedical attentionmeetingsprogramsprotocol developmentsatisfactionskillssymptom managementtool
项目摘要
DESCRIPTION (provided by applicant): Most persons with Alzheimer's disease (AD) live at home with informal (usually family) caregivers who must evaluate, manage, and communicate with health care providers about medical symptoms (e.g., pain and shortness of breath) and signs (e.g., fever and agitation). As dementia progresses, susceptibility to comorbid illness increases, communication and decision-making capacity are reduced, and transport to medical facilities becomes increasingly difficult. As a result, informal caregivers need tools that will hep them evaluate, make decisions about, and manage symptoms and signs that could represent new or evolving medical illness. The proposed project will develop, field test, refine, evaluate, finalize, and disseminate the Alzheimer's Medical Advisor (AlzMA), a multi-component toolkit that will assist informal caregivers of persons with AD to identify, evaluate, and manage new or increasing symptoms and signs of illness and then, if necessary, clearly and effectively communicate the information to health care providers. AlzMA will provide tools to evaluate a wide range of possible illnesses, include review and consultation by an on-call nurse, and be available in online and printed formats. Our long-term goal is for the AlzMA to undergo clinical trial testing and be adopted widely by medical practices and health systems serving persons with AD. During the first 2 years of the project we will develop, test, and refine the toolkit through a series of steps involving our research team, consultant clinicians, and informal caregivers (Aim 1). We will also develop and refine a measure of caregiver confidence in the ability to assess and manage symptoms and signs (Aim 2). During years 3 and 4 of the project (Aim 3) we will conduct an implementation trial of the AlzMA toolkit among 200 diverse caregivers of persons with AD who are managed by two diverse medical practices. The trial will (a) evaluate the toolkit in terms of caregiver use, knowledge gained, satisfaction of caregivers and medical practice staff, and effectiveness; (b) evaluate the following caregiver outcomes at baseline, 6 and 12 months: self-efficacy in managing dementia, anxiety, confidence in symptom and sign management, burden, and depression; and (c) on a preliminary basis, evaluate emergency department visit and hospitalization rates before and during toolkit use. Analyses will evaluate the impact of caregiver factors and toolkit format on the above outcomes. During year 5 we will disseminate components of the toolkit nationally through a web application and DVD, and make the system available to medical practices and health systems (Aim 4); in addition, we will complete the analysis and dissemination of our research results. This project represents a unique collaboration of teams from the University of North Carolina at Chapel Hill; the Duke Family Support Program; and Keona Health, a company devoted to online protocol and nurse- assisted triage and decision support on symptom evaluation and management.
描述(由申请人提供):大多数阿尔茨海默病(AD)患者与非正式(通常是家人)照顾者住在家里,他们必须评估、管理医疗保健提供者,并就医疗症状(例如疼痛和呼吸急促)和体征(例如发烧和烦躁)与医疗保健提供者进行沟通。随着痴呆症的发展,对并存疾病的易感性增加,沟通和决策能力降低,运送到医疗设施变得越来越困难。因此,非正式的照顾者需要工具来帮助他们评估、做出决定并管理可能代表新的或正在演变的疾病的症状和体征。拟议的项目将开发、现场测试、改进、评估、最终确定和传播阿尔茨海默氏症医疗顾问(阿尔茨海默病医疗顾问),这是一个多组件工具包,将帮助阿尔茨海默病患者的非正式照顾者识别、评估和管理新的或不断增加的疾病症状和体征,然后在必要时将信息清楚有效地传达给医疗保健提供者。阿尔茨海默病将提供各种工具来评估各种可能的疾病,包括由随叫随到的护士进行审查和咨询,并以在线和印刷形式提供。我们的长期目标是让老年痴呆症患者接受临床试验测试,并被服务于阿尔茨海默病患者的医疗实践和卫生系统广泛采用。在项目的头两年,我们将通过一系列步骤开发、测试和改进工具包,包括我们的研究团队、咨询临床医生和非正式护理人员(目标1)。我们还将制定和改进护理人员对评估和管理症状和体征的能力的信心的衡量标准(目标2)。在项目的第三年和第四年(目标3),我们将在由两种不同医疗实践管理的200名阿尔茨海默病患者的不同照顾者中进行阿尔茨海默氏症工具包的实施试验。该试验将(A)评估护理者使用情况、获得的知识、护理者和医务人员的满意度以及有效性;(B)在基线、6个月和12个月时评估以下护理者的结果:在管理痴呆、焦虑、对症状和体征管理的信心、负担和抑郁方面的自我效能;(C)在初步基础上,在使用工具包之前和期间评估急诊科就诊和住院率。分析将评估护理者因素和工具包格式对上述结果的影响。在第五年期间,我们将通过网络应用程序和DVD在全国范围内传播工具包的组成部分,并将该系统提供给医疗实践和卫生系统(目标4);此外,我们将完成对我们的研究结果的分析和传播。这个项目代表着来自北卡罗来纳大学教堂山分校、杜克家庭支持计划和Keona Health公司的团队的独特合作,Keona Health公司致力于在线礼仪和护士辅助的分诊以及关于症状评估和管理的决策支持。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PHILIP D SLOANE其他文献
PHILIP D SLOANE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PHILIP D SLOANE', 18)}}的其他基金
Infection Management and Antibiotic Stewardship in Nursing Homes
疗养院的感染管理和抗生素管理
- 批准号:
8666171 - 财政年份:2014
- 资助金额:
$ 48.09万 - 项目类别:
Infection Management and Antibiotic Stewardship in Nursing Homes
疗养院的感染管理和抗生素管理
- 批准号:
9060248 - 财政年份:2014
- 资助金额:
$ 48.09万 - 项目类别:
Infection Management and Antibiotic Stewardship in Nursing Homes
疗养院的感染管理和抗生素管理
- 批准号:
8840589 - 财政年份:2014
- 资助金额:
$ 48.09万 - 项目类别:
Alzheimers Medical Advisor: A Symptom and Sign Management Toolkit for Caregivers
阿尔茨海默病医疗顾问:针对护理人员的症状和体征管理工具包
- 批准号:
9099557 - 财政年份:2012
- 资助金额:
$ 48.09万 - 项目类别:
Alzheimers Medical Advisor: A Symptom and Sign Management Toolkit for Caregivers
阿尔茨海默病医疗顾问:针对护理人员的症状和体征管理工具包
- 批准号:
8554377 - 财政年份:2012
- 资助金额:
$ 48.09万 - 项目类别:
Alzheimers Medical Advisor: A Symptom and Sign Management Toolkit for Caregivers
阿尔茨海默病医疗顾问:针对护理人员的症状和体征管理工具包
- 批准号:
8471935 - 财政年份:2012
- 资助金额:
$ 48.09万 - 项目类别:
Alzheimers Medical Advisor: A Symptom and Sign Management Toolkit for Caregivers
阿尔茨海默病医疗顾问:针对护理人员的症状和体征管理工具包
- 批准号:
8690627 - 财政年份:2012
- 资助金额:
$ 48.09万 - 项目类别:
Blue-White Light Therapy for Circadian Sleep Disorders in Alzheimer's Disease
蓝白光疗法治疗阿尔茨海默病的昼夜节律睡眠障碍
- 批准号:
7690272 - 财政年份:2008
- 资助金额:
$ 48.09万 - 项目类别:
Blue-White Light Therapy for Circadian Sleep Disorders in Alzheimer's Disease
蓝白光疗法治疗阿尔茨海默病的昼夜节律睡眠障碍
- 批准号:
7532523 - 财政年份:2008
- 资助金额:
$ 48.09万 - 项目类别:
Long-Term Care that Improve Resident Quality of life
提高居民生活质量的长期护理
- 批准号:
6816857 - 财政年份:2005
- 资助金额:
$ 48.09万 - 项目类别:
相似海外基金
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 48.09万 - 项目类别:
Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 48.09万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 48.09万 - 项目类别:
Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 48.09万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 48.09万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 48.09万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 48.09万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 48.09万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 48.09万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 48.09万 - 项目类别:
Operating Grants














{{item.name}}会员




